CN112501127A - 一种重编程nk细胞的培养方法 - Google Patents

一种重编程nk细胞的培养方法 Download PDF

Info

Publication number
CN112501127A
CN112501127A CN202011518971.7A CN202011518971A CN112501127A CN 112501127 A CN112501127 A CN 112501127A CN 202011518971 A CN202011518971 A CN 202011518971A CN 112501127 A CN112501127 A CN 112501127A
Authority
CN
China
Prior art keywords
cells
cell
leu
reprogrammed
encoding gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011518971.7A
Other languages
English (en)
Other versions
CN112501127B (zh
Inventor
汤朝阳
秦乐
吴迪
冯世忠
冯嘉昆
杨乐旋
其他发明人请求不公开姓名
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Zhaotai Cell Biotechnology Co ltd
Original Assignee
Guangdong Zhaotai In Vivo Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Zhaotai In Vivo Biomedical Technology Co ltd filed Critical Guangdong Zhaotai In Vivo Biomedical Technology Co ltd
Priority to CN202011518971.7A priority Critical patent/CN112501127B/zh
Publication of CN112501127A publication Critical patent/CN112501127A/zh
Application granted granted Critical
Publication of CN112501127B publication Critical patent/CN112501127B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • C12N5/0694Cells of blood, e.g. leukemia cells, myeloma cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明提供了一种重编程NK细胞的培养方法,所述方法包括:构建表达膜固定IL‑12和CD19的人工抗原呈递细胞,将重编程NK细胞与所述人工抗原呈递细胞共培养,所述重编程NK细胞通过将靶向Bcl11b基因的RNP复合物电转入活化的T细胞制备得到。本发明采用采用表达膜固定IL‑12和CD19的人工抗原呈递细胞培养重编程NK细胞,对重编程NK细胞具有活化作用,显著提高了重编程NK细胞的数量和扩增效率,增强了重编程NK细胞的肿瘤杀伤活性。

Description

一种重编程NK细胞的培养方法
技术领域
本发明属于生物技术领域,涉及一种重编程NK细胞的培养方法。
背景技术
基于CRISPR/Cas9技术将T细胞重编程成为NK细胞,有利于克服主要组织相容性复合体(MHC)对T细胞的限制性,已成为细胞免疫治疗领域的研究热点。重编程NK细胞具有T细胞和NK细胞的双重功能,相较于T细胞或NK细胞具有显著提高的肿瘤杀伤功能,在癌症治疗中展现出了巨大的潜力。
将重编程NK细胞应用于免疫治疗的一大障碍是难以生产大量功能完全的重编程NK细胞,同时缺少体外扩增重编程NK细胞的标准方法。目前常用的NK细胞的培养方法包括血液细胞分离法、细胞因子或化学药品刺激法和饲养细胞法,但是这些方法普遍存在着操作繁琐、成本高、周期长、数量无法满足需求的问题,且不十分适用于重编程NK细胞的培养。
因此,有必要根据重编程NK细胞的特有属性,建立一种简单高效的培养方法,以期在短期内获得大量的重编程NK细胞。
发明内容
针对现有技术的不足和实际需求,本发明提供了一种重编程NK细胞的培养方法,所述方法采用表达膜固定IL-12和CD19的人工抗原呈递细胞培养重编程NK细胞,显著提高了重编程NK细胞的数量和扩增效率,增强了重编程NK细胞的肿瘤杀伤活性。
为达此目的,本发明采用以下技术方案:
第一方面,本发明提供了一种重编程NK细胞的培养方法,所述方法包括:
构建表达膜固定IL-12和CD19的人工抗原呈递细胞,将重编程NK细胞与所述人工抗原呈递细胞共培养。
本发明中,将IL-12和CD19表达于哺乳动物细胞表面构建人工抗原呈递细胞,通过与重编程NK细胞表面的受体结合用于活化重编程NK细胞,显著提高了重编程NK细胞的扩增数量,并促进了重编程NK细胞的肿瘤细胞毒性。
优选地,所述IL-12包括IL-12A和IL-12B,所述IL-12通过IL-12B与CD8α跨膜区形成融合蛋白、表达在所述人工抗原递呈细胞表面。
优选地,所述IL-12A包括如SEQ ID NO:1所示的氨基酸序列;
SEQ ID NO:1:
MWPPGSASQPPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRA。
优选地,所述IL-12B包括如SEQ ID NO:2所示的氨基酸序列;
SEQ ID NO:2:
MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYY。
优选地,所述CD19包括SEQ ID NO:3所示的氨基酸序列;
SEQ ID NO:3:
MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHL。
优选地,所述CD8α跨膜区包括SEQ ID NO:4所示的氨基酸序列;
SEQ ID NO:4:
IYIWAPLAGTCGVLLLSLVITLYC。
优选地,所述人工抗原呈递细胞的构建方法包括:
构建包括IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因或CD19编码基因中的任意一种或至少两种的组合的慢病毒载体,利用慢病毒系统将IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因和CD19编码基因导入K562细胞。
优选地,所述重编程NK细胞的制备方法包括:将靶向Bcl11b基因的RNP复合物电转入活化的T细胞,得到重编程NK细胞,其中,所述RNP复合物包括靶向Bcl11b基因的crRNA、tracrRNA和Cas9蛋白。
优选地,所述crRNA包括SEQ ID NO:5所示的核酸序列;
SEQ ID NO:5:gaagcagtgtggcggcagctgttttagagcta。
优选地,所述tracrRNA包括SEQ ID NO:6所示的核酸序列;
SEQ ID NO:6:tagcaagttaaaataaggctagtcatttatcacattgaaaatctggcaccgagtcggtg。
优选地,所述电转的电压为800~2500V,例如可以是800V、900V、1000V、1100V、1200V、1300V、1400V、1500V、1600V、1700V、1800V、1900V、2000V、2100V、2200V、2300V、2400V或2500V。
优选地,所述重编程NK细胞与所述人工抗原递呈细胞的数量比为(0.25~1):1,例如可以是0.25:1、0.3:1、0.35:1、0.4:1、0.45:1、0.5:1、0.55:1、0.6:1、0.65:1、0.7:1、0.75:1、0.8:1、0.85:1、0.9:1、0.95:1或1:1。
优选地,所述共培养的时间为3~14天,例如可以是3天、4天、5天、6天、7天、8天、9天、10天、11天、12天或13天。
优选地,所述方法还包括对共培养的重编程NK细胞与人工抗原递呈细胞进行辐照的步骤。
优选地,所述辐照的剂量为50~500Gy,例如可以是50Gy、100Gy、150Gy、200Gy、250Gy、300Gy、350Gy、400Gy、450Gy或500Gy。
作为优选技术方案,本发明提供了一种重编程NK细胞的培养方法,所述方法包括以下步骤:
(1)构建包括IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因或CD19编码基因中的任意一种或至少两种的组合的慢病毒载体,利用慢病毒系统将IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因和CD19编码基因导入K562细胞,构建表达膜固定IL-12和CD19的人工抗原呈递细胞;
将靶向Bcl11b基因的crRNA、tracrRNA和Cas9蛋白组成的RNP复合物在800~2500V下电转入活化的T细胞,得到重编程NK细胞;
(2)将所述重编程NK细胞与所述人工抗原递呈细胞按照数量比为(0.25~1):1共培养3~14天,期间进行50~500Gy辐照,进行重编程NK细胞扩增。
第二方面,本发明提供了一种重编程NK细胞,所述重编程NK细胞采用第一方面所述的方法培养得到。
与现有技术相比,本发明具有如下有益效果:
(1)本发明采用表达膜固定IL-12和CD19的人工抗原呈递细胞与重编程NK细胞共培养,对重编程NK细胞具有活化作用,显著提高了重编程NK细胞的扩增数量,实现了短期内迅速获得大量高纯度重编程NK细胞的效果;
(2)本发明培养获得的重编程NK细胞杀瘤能力强、杀伤功能稳定、寿命长。
附图说明
图1为重编程NK细胞与IL-12/CD19-K562共培养后的体外扩增能力;
图2为重编程NK细胞与IL-12/CD19-K562共培养后的肿瘤细胞毒性。
具体实施方式
为进一步阐述本发明所采取的技术手段及其效果,以下结合实施例和附图对本发明作进一步地说明。可以理解的是,此处所描述的具体实施方式仅仅用于解释本发明,而非对本发明的限定。
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。
实施例1人工抗原呈递细胞的构建
人工合成T2A连接的IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因、CD19编码基因,构建融合基因,融合基因的两端添加EcoRI和BamHI酶切位点,经过EcoRI和BamHI酶切后,克隆入pCDH质粒,构建慢病毒载体;
将慢病毒载体和辅助质粒pMD2.G、psPAX2与转染试剂PEI混合后,导入293T细胞中,培养6h更换新鲜培养基,包装24h、48h和72h后,收取病毒上清进行1000g离心10min,0.45μm滤器过滤得到重组慢病毒;
将野生型K562细胞重悬于10mL Opti-MEM中,300×g离心10min,将细胞沉淀重悬于100μL缓冲液中,加入重组慢病毒,并加入8μg/mL polybrene和300IU/mL IL-2,置于37℃、5%CO2培养箱培养;24h后,300g离心5min,去上清,用含300IU/mL IL-2的新鲜培养基重悬细沉淀,即得人工抗原呈递细胞。
实施例2RNP复合物的制备
根据Bcl11b基因设计crRNA(SEQ ID NO:5)和tracrRNA(SEQ ID NO:6),进行基因合成,将crRNA、tracrRNA和Cas9蛋白按照1:2:2的比例混匀,采用OPTI-MEMTM配制得到浓度为40μM RNP混合溶液,待用。
实施例3重编程NK细胞的制备与扩增
(1)采用Ficoll密度梯度离心试剂盒(GE公司)从全血中分离外周血单个核细胞(PBMC),去除红细胞后,利用MACS Pan-T磁珠分选出T细胞,分选出来的T细胞用MACS激活试剂盒激活24小时,采用T细胞培养基稀释至细胞浓度为2.5×106个/mL;
(2)300×g离心10min,将细胞沉淀重悬于100μL Opti-MEM中,加入浓度为40μM的RNP复合物,混匀后转移至电Lonza电击杯,将电击杯置于Lonza4D-NucleofectorTM X Unit(单电击杯模块中),进行电转,设定电转的电压为800V,时间为4ms;
(3)将电转后的细胞与实施例1制备的表达IL-12和CD19的K562在1:1的比例下共培养3~14天,并进行50Gy辐照,进行重编程NK细胞扩增。
本实施例同时设置以下对照组:
IL-12对照组:RNP复合物电转后的细胞与IL-12+K562共培养3~14天;
CD19对照组;RNP复合物电转后的细胞与CD19+K562共培养3~14天;
空白对照组:RNP复合物电转后的细胞与K562细胞共培养3~14天。
实施例4重编程NK细胞的体外扩增能力
对实施例3的重编程NK细胞进行生长状态检测,结果如图1所示,IL-12+CD19+K562细胞对重编程NK细胞扩增的促进作用显著高于其他对照组,共培养14天后,重编程NK细胞的数量增长约40倍,说明采用IL-12+CD19+K562细胞作为人工抗原呈递细胞,对经电转RNP复合物制备的重编程NK细胞具有促进体外扩增的作用。
实施例5重编程NK细胞的肿瘤细胞毒性
将实施例3的重编程NK细胞、T细胞和NK细胞分别与5×103个卵巢癌细胞系SKOV3共培养于U型96孔板中,效应细胞与靶标细胞的比例(E:T)为1:1,每组实验重复3次;
经过18小时的共培养后,向96孔板中加入100μL/孔的荧光素酶底物(1×),将细胞重悬混匀,立即通过多功能酶标仪测定RLU(relative light unit),测定时间为1秒,利用荧光素酶(Luciferase)定量杀伤效率评估方法,体外比较不同重编程NK细胞对SKOV3的杀伤作用,杀伤比例计算公式如下:
100%×(对照孔读数-实验孔读数)/对照孔读数(不加细胞的空白组读数可以忽略)
结果如图2所示,重编程NK细胞的杀伤效率高于T细胞和NK细胞,而与IL-12+CD19+K562细胞共培养获得的重编程NK细胞的杀伤效率更高。
综上所述,本发明采用表达膜固定IL-12和CD19的人工抗原呈递细胞与重编程NK细胞共培养,得到的重编程NK细胞保留有T细胞和NK细胞的固有属性,同时具有增强的杀瘤能力,在细胞免疫治疗领域具有重要意义。
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
SEQUENCE LISTING
<110> 广东昭泰体内生物医药科技有限公司
<120> 一种重编程NK细胞的培养方法
<130> 20201214
<160> 6
<170> PatentIn version 3.3
<210> 1
<211> 240
<212> PRT
<213> 人工序列
<400> 1
Met Trp Pro Pro Gly Ser Ala Ser Gln Pro Pro Pro Ser Pro Ala Ala
1 5 10 15
Ala Thr Gly Leu His Pro Ala Ala Arg Pro Val Ser Leu Gln Cys Arg
20 25 30
Leu Ser Met Cys Pro Ala Arg Ser Leu Leu Leu Val Ala Thr Leu Val
35 40 45
Leu Leu Asp His Leu Ser Leu Ala Arg Asn Leu Pro Val Ala Thr Pro
50 55 60
Asp Pro Gly Met Phe Pro Cys Leu His His Ser Gln Asn Leu Leu Arg
65 70 75 80
Ala Val Ser Asn Met Leu Gln Lys Ala Arg Gln Thr Leu Glu Phe Tyr
85 90 95
Pro Cys Thr Ser Glu Glu Ile Asp His Glu Asp Ile Thr Lys Asp Lys
100 105 110
Thr Ser Thr Val Glu Ala Cys Leu Pro Leu Glu Leu Thr Lys Asn Glu
115 120 125
Ser Cys Leu Asn Ser Arg Glu Thr Ser Phe Ile Thr Asn Gly Ser Cys
130 135 140
Leu Ala Ser Arg Lys Thr Ser Phe Met Met Ala Leu Cys Leu Ser Ser
145 150 155 160
Ile Tyr Glu Asp Leu Lys Met Tyr Gln Val Glu Phe Lys Thr Met Asn
165 170 175
Ala Lys Leu Leu Met Asp Pro Lys Arg Gln Ile Phe Leu Asp Gln Asn
180 185 190
Met Leu Ala Val Ile Asp Glu Leu Met Gln Ala Leu Asn Phe Asn Ser
195 200 205
Glu Thr Val Pro Gln Lys Ser Ser Leu Glu Glu Pro Asp Phe Tyr Lys
210 215 220
Thr Lys Ile Lys Leu Cys Ile Leu Leu His Ala Phe Arg Ile Arg Ala
225 230 235 240
<210> 2
<211> 312
<212> PRT
<213> 人工序列
<400> 2
Met Cys His Gln Gln Leu Val Ile Ser Trp Phe Ser Leu Val Phe Leu
1 5 10 15
Ala Ser Pro Leu Val Ala Ile Trp Glu Leu Lys Lys Asp Val Tyr Val
20 25 30
Val Glu Leu Asp Trp Tyr Pro Asp Ala Pro Gly Glu Met Val Val Leu
35 40 45
Thr Cys Asp Thr Pro Glu Glu Asp Gly Ile Thr Trp Thr Leu Asp Gln
50 55 60
Ser Ser Glu Val Leu Gly Ser Gly Lys Thr Leu Thr Ile Gln Val Lys
65 70 75 80
Glu Phe Gly Asp Ala Gly Gln Tyr Thr Cys His Lys Gly Gly Glu Val
85 90 95
Leu Ser His Ser Leu Leu Leu Leu His Lys Lys Glu Asp Gly Ile Trp
100 105 110
Ser Thr Asp Ile Leu Lys Asp Gln Lys Glu Pro Lys Asn Lys Thr Phe
115 120 125
Leu Arg Cys Glu Ala Lys Asn Tyr Ser Gly Arg Phe Thr Cys Trp Trp
130 135 140
Leu Thr Thr Ile Ser Thr Asp Leu Thr Phe Ser Val Lys Ser Ser Arg
145 150 155 160
Gly Ser Ser Asp Pro Gln Gly Val Thr Cys Gly Ala Ala Thr Leu Ser
165 170 175
Ala Glu Arg Val Arg Gly Asp Asn Lys Glu Tyr Glu Tyr Ser Val Glu
180 185 190
Cys Gln Glu Asp Ser Ala Cys Pro Ala Ala Glu Glu Ser Leu Pro Ile
195 200 205
Glu Val Met Val Asp Ala Val His Lys Leu Lys Tyr Glu Asn Tyr Thr
210 215 220
Ser Ser Phe Phe Ile Arg Lys Pro Asp Pro Pro Lys Asn Leu Gln Leu
225 230 235 240
Lys Pro Leu Lys Asn Ser Arg Gln Val Glu Val Ser Trp Glu Tyr Pro
245 250 255
Asp Thr Trp Ser Thr Pro His Ser Tyr Phe Ser Leu Thr Phe Cys Val
260 265 270
Gln Val Gln Gly Lys Ser Lys Arg Glu Lys Lys Asp Arg Val Phe Thr
275 280 285
Asp Lys Thr Ser Ala Thr Val Ile Cys Arg Lys Asn Ala Ser Ile Ser
290 295 300
Val Arg Ala Gln Asp Arg Tyr Tyr
305 310
<210> 3
<211> 313
<212> PRT
<213> 人工序列
<400> 3
Met Pro Pro Pro Arg Leu Leu Phe Phe Leu Leu Phe Leu Thr Pro Met
1 5 10 15
Glu Val Arg Pro Glu Glu Pro Leu Val Val Lys Val Glu Glu Gly Asp
20 25 30
Asn Ala Val Leu Gln Cys Leu Lys Gly Thr Ser Asp Gly Pro Thr Gln
35 40 45
Gln Leu Thr Trp Ser Arg Glu Ser Pro Leu Lys Pro Phe Leu Lys Leu
50 55 60
Ser Leu Gly Leu Pro Gly Leu Gly Ile His Met Arg Pro Leu Ala Ile
65 70 75 80
Trp Leu Phe Ile Phe Asn Val Ser Gln Gln Met Gly Gly Phe Tyr Leu
85 90 95
Cys Gln Pro Gly Pro Pro Ser Glu Lys Ala Trp Gln Pro Gly Trp Thr
100 105 110
Val Asn Val Glu Gly Ser Gly Glu Leu Phe Arg Trp Asn Val Ser Asp
115 120 125
Leu Gly Gly Leu Gly Cys Gly Leu Lys Asn Arg Ser Ser Glu Gly Pro
130 135 140
Ser Ser Pro Ser Gly Lys Leu Met Ser Pro Lys Leu Tyr Val Trp Ala
145 150 155 160
Lys Asp Arg Pro Glu Ile Trp Glu Gly Glu Pro Pro Cys Leu Pro Pro
165 170 175
Arg Asp Ser Leu Asn Gln Ser Leu Ser Gln Asp Leu Thr Met Ala Pro
180 185 190
Gly Ser Thr Leu Trp Leu Ser Cys Gly Val Pro Pro Asp Ser Val Ser
195 200 205
Arg Gly Pro Leu Ser Trp Thr His Val His Pro Lys Gly Pro Lys Ser
210 215 220
Leu Leu Ser Leu Glu Leu Lys Asp Asp Arg Pro Ala Arg Asp Met Trp
225 230 235 240
Val Met Glu Thr Gly Leu Leu Leu Pro Arg Ala Thr Ala Gln Asp Ala
245 250 255
Gly Lys Tyr Tyr Cys His Arg Gly Asn Leu Thr Met Ser Phe His Leu
260 265 270
Glu Ile Thr Ala Arg Pro Val Leu Trp His Trp Leu Leu Arg Thr Gly
275 280 285
Gly Trp Lys Val Ser Ala Val Thr Leu Ala Tyr Leu Ile Phe Cys Leu
290 295 300
Cys Ser Leu Val Gly Ile Leu His Leu
305 310
<210> 4
<211> 24
<212> PRT
<213> 人工序列
<400> 4
Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu
1 5 10 15
Ser Leu Val Ile Thr Leu Tyr Cys
20
<210> 5
<211> 32
<212> DNA
<213> 人工序列
<400> 5
gaagcagtgt ggcggcagct gttttagagc ta 32
<210> 6
<211> 59
<212> DNA
<213> 人工序列
<400> 6
tagcaagtta aaataaggct agtcatttat cacattgaaa atctggcacc gagtcggtg 59

Claims (10)

1.一种重编程NK细胞的培养方法,其特征在于,所述方法包括:
构建表达膜固定IL-12和CD19的人工抗原呈递细胞,将重编程NK细胞与所述人工抗原呈递细胞共培养。
2.根据权利要求1所述的方法,其特征在于,所述IL-12包括IL-12A和IL-12B,所述IL-12通过IL-12B与CD8α跨膜区形成融合蛋白、表达在所述人工抗原递呈细胞表面;
优选地,所述IL-12A包括如SEQ ID NO:1所示的氨基酸序列;
优选地,所述IL-12B包括如SEQ ID NO:2所示的氨基酸序列;
优选地,所述CD19包括SEQ ID NO:3所示的氨基酸序列;
优选地,所述CD8α跨膜区包括SEQ ID NO:4所示的氨基酸序列。
3.根据权利要求1或2所述的方法,其特征在于,所述人工抗原呈递细胞的构建方法包括:
构建包括IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因或CD19编码基因中的任意一种或至少两种的组合的慢病毒载体,利用慢病毒系统将IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因和CD19编码基因导入K562细胞。
4.根据权利要求1-3任一项所述的方法,其特征在于,所述重编程NK细胞的制备方法包括:将靶向Bcl11b基因的RNP复合物电转入活化的T细胞,得到重编程NK细胞,其中,所述RNP复合物包括靶向Bcl11b基因的crRNA、tracrRNA和Cas9蛋白。
5.根据权利要求4所述的方法,其特征在于,所述crRNA包括SEQ ID NO:5所示的核酸序列;
优选地,所述tracrRNA包括SEQ ID NO:6所示的核酸序列。
6.根据权利要求4或5所述的方法,其特征在于,所述电转的电压为800~2500V。
7.根据权利要求1-6任一项所述的方法,其特征在于,所述重编程NK细胞与所述人工抗原递呈细胞的数量比为(0.25~1):1;
优选地,所述共培养的时间为3~14天。
8.根据权利要求1-7任一项所述的方法,其特征在于,所述方法还包括对共培养的重编程NK细胞与人工抗原递呈细胞进行辐照的步骤;
优选地,所述辐照的剂量为50~500Gy。
9.根据权利要求1-8任一项所述的方法,其特征在于,所述方法包括以下步骤:
(1)构建包括IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因或CD19编码基因中的任意一种或至少两种的组合的慢病毒载体,利用慢病毒系统将IL-12A编码基因、IL-12B和CD8α跨膜区融合蛋白编码基因和CD19编码基因导入K562细胞,构建表达膜固定IL-12和CD19的人工抗原呈递细胞;
将靶向Bcl11b基因的crRNA、tracrRNA和Cas9蛋白组成的RNP复合物在800~2500V下电转入活化的T细胞,得到重编程NK细胞;
(2)将所述重编程NK细胞与所述人工抗原递呈细胞按照数量比为(0.25~1):1共培养3~14天,期间进行50~500Gy辐照,进行重编程NK细胞扩增。
10.一种重编程NK细胞,其特征在于,所述重编程NK细胞采用权利要求1-9任一项所述的方法培养得到。
CN202011518971.7A 2020-12-21 2020-12-21 一种重编程nk细胞的培养方法 Active CN112501127B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011518971.7A CN112501127B (zh) 2020-12-21 2020-12-21 一种重编程nk细胞的培养方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011518971.7A CN112501127B (zh) 2020-12-21 2020-12-21 一种重编程nk细胞的培养方法

Publications (2)

Publication Number Publication Date
CN112501127A true CN112501127A (zh) 2021-03-16
CN112501127B CN112501127B (zh) 2023-10-10

Family

ID=74922867

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011518971.7A Active CN112501127B (zh) 2020-12-21 2020-12-21 一种重编程nk细胞的培养方法

Country Status (1)

Country Link
CN (1) CN112501127B (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102586185A (zh) * 2012-03-12 2012-07-18 浙江中赢方舟生物工程股份有限公司 一种k562细胞扩增激活nk细胞的方法
CN106754730A (zh) * 2017-02-22 2017-05-31 上海科医联创生物科技有限公司 一种高效扩增nk细胞的方法
CN110494557A (zh) * 2017-03-27 2019-11-22 新加坡国立大学 用于离体扩增和活化自然杀伤细胞的刺激细胞系
WO2020021045A2 (en) * 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesù (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CN110964698A (zh) * 2019-12-25 2020-04-07 杭州中赢生物医疗科技有限公司 一种人工抗原递呈细胞及其制备方法和应用
CN111607569A (zh) * 2020-06-01 2020-09-01 广东昭泰体内生物医药科技有限公司 一种基于CRISPR/Cas9重编程ITNK细胞的方法
CN112029721A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种活性增强型nk细胞的制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102586185A (zh) * 2012-03-12 2012-07-18 浙江中赢方舟生物工程股份有限公司 一种k562细胞扩增激活nk细胞的方法
CN106754730A (zh) * 2017-02-22 2017-05-31 上海科医联创生物科技有限公司 一种高效扩增nk细胞的方法
CN110494557A (zh) * 2017-03-27 2019-11-22 新加坡国立大学 用于离体扩增和活化自然杀伤细胞的刺激细胞系
WO2020021045A2 (en) * 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesù (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
CN110964698A (zh) * 2019-12-25 2020-04-07 杭州中赢生物医疗科技有限公司 一种人工抗原递呈细胞及其制备方法和应用
CN111607569A (zh) * 2020-06-01 2020-09-01 广东昭泰体内生物医药科技有限公司 一种基于CRISPR/Cas9重编程ITNK细胞的方法
CN112029721A (zh) * 2020-09-09 2020-12-04 广东昭泰体内生物医药科技有限公司 一种活性增强型nk细胞的制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUK SEONG BAE 等: "Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line", 《BLOOD RES.》 *
MINH-TRANG THI PHAN 等: "Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells", 《METHODS MOL BIOL.》 *

Also Published As

Publication number Publication date
CN112501127B (zh) 2023-10-10

Similar Documents

Publication Publication Date Title
CN105624107B (zh) 一种多种淋巴细胞亚群的扩增方法及其应用
WO2018204493A1 (en) Compositions and methods for gene editing in t cells using crispr/cpf1
CN111566221B (zh) 用于nk细胞转导的方法
CN110818803B (zh) 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用
CN110684730B (zh) 一种利用滋养细胞高效扩增nk细胞的制备方法
CN111172115A (zh) 一种体外高效扩增nk细胞的方法
CN112251412B (zh) 一种靶向bcma的嵌合抗原受体t细胞及其应用
CN111848820B (zh) Cd19和bcma双靶点嵌合抗原受体及其应用
CN111801104A (zh) Car-t细胞的封闭系统制造过程
CN112029729A (zh) Cd19和cd22双靶点嵌合抗原受体nk细胞及其应用
CN112626027A (zh) 一种Treg细胞培养方法
CN112210539A (zh) 一种第四代car-t细胞及其应用
CN112226462A (zh) 共表达分泌型il-7和选择性ccl19的表达载体及其应用
CN113684184A (zh) 一种人多能干细胞制备靶向cd19的嵌合抗原受体nk细胞的方法与应用
CN112063653A (zh) 一种基于电转重编程质粒制备nk样细胞的方法
CN112592898B (zh) 一种重编程nk饲养细胞及其制备方法和应用
CN112175998A (zh) 一种嵌合抗原受体t细胞及其应用
CN112626028B (zh) 一种激活nk样细胞的工程化细胞及其制备方法和应用
CN112501127B (zh) 一种重编程nk细胞的培养方法
WO2022007665A1 (zh) 非病毒方法制备稳定高表达嵌合受体的nk细胞
CN116254234A (zh) 基因修饰的k562细胞及其在体外培养nk细胞中的应用
CN112048480A (zh) 一种基于电转制备nk样细胞的方法
CN112608901B (zh) 一种人工抗原呈递细胞及其制备方法和应用
CN114134182A (zh) 一种新型免疫细胞的制备方法及其应用
CN111548998A (zh) 一种分泌pd-1抗体的长寿浆细胞及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20211228

Address after: No. 833, Shunde street, Shunde District, Guangdong Province

Applicant after: Tang Chaoyang

Address before: 510663 units 517-519, 518-520, 5th floor, Zone D, Guangzhou Science and technology innovation base, No.80, Science City, Langyue Road, Guangzhou high tech Industrial Development Zone, Guangdong Province

Applicant before: GUANGDONG ZHAOTAI INVIVO BIOMEDICINE Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230526

Address after: 528300 one of 0501, No. 3, Zhicheng Road, fengsha village, Daliang street, Shunde District, Foshan City, Guangdong Province

Applicant after: Guangdong Zhaotai Cell Biotechnology Co.,Ltd.

Address before: No. 833, Shunde street, Shunde District, Guangdong Province

Applicant before: Tang Chaoyang

GR01 Patent grant
GR01 Patent grant